LLY
Eli Lilly and CompanyHealth Caresp500Everything we've seen
- ·May 12, 3:01 PMstreamnews
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Eli Lilly is a strong buy as 2026 guidance rose $2B on surging Zepbound sales and deep pipeline momentum. Learn why LLY stock is a strong buy.
- ·May 12, 3:01 PMstreamnews
Hims Labs AI And GLP 1 Push Test Stock Valuation Story
Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...
- ·May 12, 3:01 PMstreamnews
Eli Lilly, GLP-1 Troubles Are Dragging Down This Healthcare ETF
Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.
- ·May 12, 3:01 PMstreamnews
Lightning Round: Nokia is a buy, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Nokia, Chewy, Ford, Eli Lilly, Caterpillar, and more.
- ·May 12, 3:01 PMstreamnews
Tech Dominates; Nvidia’s Market Value Exceeds Entire Healthcare Sector of S&P 500
The tech sector has a record-high market cap of over $23 trillion, a 37% weighting in the S&P 500, the largest percentage ever.
- ·May 12, 3:01 PMstreamnews
Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Eli Lilly and Company is one of the best cancer stocks. TheFly reported on May 5 that Barclays increased its valuation outlook for LLY, raising the price target to $1,400 from $1,350 while maintaining an Overweight rating. The […]
- ·May 12, 3:01 PMstreamnews
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
Exploring PRIMECAP Management (Trades, Portfolio)'s Recent 13F Filing and Investment Strategies
- ·May 12, 3:01 PMstreamnews
Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...
- ·May 12, 3:01 PMstreamnews
Roche And Lilly's Elecsys pTau217 Wins CE Mark As First Single-Assay Blood Test Offering Spinal Fluid-Comparable Accuracy To Rule In And Rule Out Alzheimer's Amyloid Pathology
Elecsys pTau217 is the first blood test for Alzheimer's disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for
- ·May 12, 3:01 PMstreamnews
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.1,2,5While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.1,2,4,7,8,11Diagnosing d
- ·May 12, 3:01 PMstreamnews
Hims & Hers plunges after weight-loss pivot hits quarterly results
Shares of Hims & Hers Health fell 15% premarket on Tuesday after the telehealth company missed Wall Street estimates for first-quarter revenue and posted a surprise loss, hurt by changes in its...
- ·May 12, 3:01 PMstreamnews
Jim Cramer Won't 'Dump' This Medical Device Maker, Passes On Ford
"I don't understand how this thing could have fallen so fast," the Mad Money host said of the medical device maker.
- ·May 12, 3:01 PMstreamnews
Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
- ·May 12, 3:01 PMstreamnews
Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection
Roche secured European CE Mark approval for its Elecsys pTau217 Alzheimer's blood test developed with Eli Lilly.
- ·May 12, 3:01 PMstreamnews
Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom
The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom
- ·May 12, 3:01 PMstreamnews
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.
- ·May 12, 3:01 PMstreamnews
Trinity's TGaS Advisors Announces Winners of 9th Annual Best of Benchmark Awards
Trinity, a leader in strategy, insights and analytics for the life sciences industry, announced the winners of the TGaS Advisors Best of Benchmark (BoBs) Awards. The awards, presented annually, recognize operational excellence across pharmaceutical organizations based on TGaS benchmarking data.
- ·May 12, 3:01 PMstreamnews
The 3 Best S&P 500 Stocks to Buy Now
These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.
- ·May 12, 3:01 PMstreamnews
Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
- ·May 12, 3:01 PMstreamnews
GLP-1 Wars: Winners & Losers
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
- ·May 12, 3:01 PMstreamnews
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
- ·May 12, 3:01 PMstreamnews
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Eli Lilly and Company (NYSE: LLY) today announced an initiative to support nationwide nutritious food distribution as part of the company's 150th anniversary, through charitable support of trusted community organizations in the United States. With Lilly's support, community organizations will be able to distribute approximately 500,000 meals to those in need across 15 communities. Lilly's support will also help one of these organizations build long-term cold storage infrastructure at 150 food pa
- ·May 12, 3:01 PMstreamnews
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
- ?May 12, 3:01 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY has moved up 2.55% today but there are no recent headlines or clear catalysts explaining the move, making it difficult to assess whether this is fundamentally driven or a technical/flow-based rally. The macro context (elevated 5-year inflation expectations) is not directly supportive of pharma/large-cap biotech continuation. With only 45 minutes remaining until the forced close cutoff, there is limited time for meaningful additional upside even if momentum persists, and late-day profit-taking risk is elevated after a ~$25 intraday gain.
- !May 12, 3:01 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY has moved up 2.55% today but there are no recent headlines or clear catalysts explaining the move, making it difficult to assess whether this is fundamentally driven or a technical/flow-based rally. The macro context (elevated 5-year inflation expectations) is not directly supportive of pharma/large-cap biotech continuation. With only 45 minutes remaining until the forced close cutoff, there is limited time for meaningful additional upside even if momentum persists, and late-day profit-taking risk is elevated after a ~$25 intraday gain.
- ·May 12, 2:58 PMstreamnews
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Eli Lilly is a strong buy as 2026 guidance rose $2B on surging Zepbound sales and deep pipeline momentum. Learn why LLY stock is a strong buy.
- ·May 12, 2:58 PMstreamnews
Hims Labs AI And GLP 1 Push Test Stock Valuation Story
Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...
- ·May 12, 2:58 PMstreamnews
Eli Lilly, GLP-1 Troubles Are Dragging Down This Healthcare ETF
Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.
- ·May 12, 2:58 PMstreamnews
Lightning Round: Nokia is a buy, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Nokia, Chewy, Ford, Eli Lilly, Caterpillar, and more.
- ·May 12, 2:58 PMstreamnews
Tech Dominates; Nvidia’s Market Value Exceeds Entire Healthcare Sector of S&P 500
The tech sector has a record-high market cap of over $23 trillion, a 37% weighting in the S&P 500, the largest percentage ever.
- ·May 12, 2:58 PMstreamnews
Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Eli Lilly and Company is one of the best cancer stocks. TheFly reported on May 5 that Barclays increased its valuation outlook for LLY, raising the price target to $1,400 from $1,350 while maintaining an Overweight rating. The […]
- ·May 12, 2:58 PMstreamnews
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
Exploring PRIMECAP Management (Trades, Portfolio)'s Recent 13F Filing and Investment Strategies
- ·May 12, 2:58 PMstreamnews
Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...
- ·May 12, 2:58 PMstreamnews
Roche And Lilly's Elecsys pTau217 Wins CE Mark As First Single-Assay Blood Test Offering Spinal Fluid-Comparable Accuracy To Rule In And Rule Out Alzheimer's Amyloid Pathology
Elecsys pTau217 is the first blood test for Alzheimer's disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for
- ·May 12, 2:58 PMstreamnews
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.1,2,5While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.1,2,4,7,8,11Diagnosing d
- ·May 12, 2:58 PMstreamnews
Hims & Hers plunges after weight-loss pivot hits quarterly results
Shares of Hims & Hers Health fell 15% premarket on Tuesday after the telehealth company missed Wall Street estimates for first-quarter revenue and posted a surprise loss, hurt by changes in its...
- ·May 12, 2:58 PMstreamnews
Jim Cramer Won't 'Dump' This Medical Device Maker, Passes On Ford
"I don't understand how this thing could have fallen so fast," the Mad Money host said of the medical device maker.
- ·May 12, 2:58 PMstreamnews
Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
- ·May 12, 2:58 PMstreamnews
Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection
Roche secured European CE Mark approval for its Elecsys pTau217 Alzheimer's blood test developed with Eli Lilly.
- ·May 12, 2:58 PMstreamnews
Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom
The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom
- ·May 12, 2:58 PMstreamnews
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.
- ·May 12, 2:58 PMstreamnews
Trinity's TGaS Advisors Announces Winners of 9th Annual Best of Benchmark Awards
Trinity, a leader in strategy, insights and analytics for the life sciences industry, announced the winners of the TGaS Advisors Best of Benchmark (BoBs) Awards. The awards, presented annually, recognize operational excellence across pharmaceutical organizations based on TGaS benchmarking data.
- ·May 12, 2:58 PMstreamnews
The 3 Best S&P 500 Stocks to Buy Now
These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.
- ·May 12, 2:58 PMstreamnews
Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
- ·May 12, 2:58 PMstreamnews
GLP-1 Wars: Winners & Losers
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
- ·May 12, 2:58 PMstreamnews
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
- ·May 12, 2:58 PMstreamnews
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Eli Lilly and Company (NYSE: LLY) today announced an initiative to support nationwide nutritious food distribution as part of the company's 150th anniversary, through charitable support of trusted community organizations in the United States. With Lilly's support, community organizations will be able to distribute approximately 500,000 meals to those in need across 15 communities. Lilly's support will also help one of these organizations build long-term cold storage infrastructure at 150 food pa
- ·May 12, 2:58 PMstreamnews
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
- ·May 12, 2:56 PMstreamnews
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Eli Lilly and Company (NYSE: LLY) today announced an initiative to support nationwide nutritious food distribution as part of the company's 150th anniversary, through charitable support of trusted community organizations in the United States. With Lilly's support, community organizations will be able to distribute approximately 500,000 meals to those in need across 15 communities. Lilly's support will also help one of these organizations build long-term cold storage infrastructure at 150 food pa
- ·May 12, 2:56 PMstreamnews
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
- ?May 12, 2:45 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY has moved up 2.54% today with no accompanying news catalysts or earnings events visible in the headlines, making it difficult to attribute the move to a durable fundamental driver. The macro context around elevated inflation expectations (T5YIE at 1.9σ above trend) is more relevant to Gold, Energy, and TIPS sectors, not large-cap pharma, providing no tailwind support. With only 60 minutes remaining until the forced close, there is limited time for meaningful continuation, and without a clear catalyst the move risks fading or consolidating into the close.
- !May 12, 2:45 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY has moved up 2.54% today with no accompanying news catalysts or earnings events visible in the headlines, making it difficult to attribute the move to a durable fundamental driver. The macro context around elevated inflation expectations (T5YIE at 1.9σ above trend) is more relevant to Gold, Energy, and TIPS sectors, not large-cap pharma, providing no tailwind support. With only 60 minutes remaining until the forced close, there is limited time for meaningful continuation, and without a clear catalyst the move risks fading or consolidating into the close.
- ?May 12, 2:31 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up 2.42% with no identifiable news catalyst driving the move, making it difficult to assess whether momentum will sustain into the close. The macro context around elevated 5-year inflation expectations is not directly relevant to a large-cap pharma name like LLY. With 74 minutes remaining, there is some time for continuation, but absent a clear fundamental catalyst, the move could easily fade or consolidate near current levels.
- !May 12, 2:31 PMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
LLY is up 2.42% with no identifiable news catalyst driving the move, making it difficult to assess whether momentum will sustain into the close. The macro context around elevated 5-year inflation expectations is not directly relevant to a large-cap pharma name like LLY. With 74 minutes remaining, there is some time for continuation, but absent a clear fundamental catalyst, the move could easily fade or consolidate near current levels.
- ?May 12, 2:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up 2.41% with no identifiable catalyst from recent headlines to explain or sustain the move, making it difficult to assign directional conviction. The macro context (elevated inflation expectations via T5YIE) is not directly relevant to large-cap pharma and provides no sector tailwind. With 90 minutes remaining and no clear fundamental driver, the move may represent profit-taking risk or a gap-fill scenario rather than a sustained trend into the close.
- !May 12, 2:15 PMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
LLY is up 2.41% with no identifiable catalyst from recent headlines to explain or sustain the move, making it difficult to assign directional conviction. The macro context (elevated inflation expectations via T5YIE) is not directly relevant to large-cap pharma and provides no sector tailwind. With 90 minutes remaining and no clear fundamental driver, the move may represent profit-taking risk or a gap-fill scenario rather than a sustained trend into the close.
- ?May 12, 2:00 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up 2.60% with no recent headlines to explain the catalyst, making it difficult to assess whether this move has fundamental support or is noise/technical in nature. The macro context (elevated 5Y inflation expectations) is not directly relevant to a large-cap pharmaceutical like LLY, offering no sector tailwind. With 105 minutes remaining and no clear news-driven catalyst, the probability of sustained continuation into the close is roughly coin-flip, and a cautious uncertain stance is warranted.
- !May 12, 2:00 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY is up 2.60% with no recent headlines to explain the catalyst, making it difficult to assess whether this move has fundamental support or is noise/technical in nature. The macro context (elevated 5Y inflation expectations) is not directly relevant to a large-cap pharmaceutical like LLY, offering no sector tailwind. With 105 minutes remaining and no clear news-driven catalyst, the probability of sustained continuation into the close is roughly coin-flip, and a cautious uncertain stance is warranted.
- ?May 12, 1:30 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up ~3% intraday but there are no recent headlines or identifiable catalysts explaining the move, making it difficult to distinguish a sustained trend from a gap or thin-volume spike. The macro context (elevated 5Y inflation expectations) does not directly favor pharmaceutical/biotech names like LLY. With 135 minutes remaining, there is time for continuation, but without a clear news-driven catalyst, mean-reversion risk is meaningful and confidence in directional continuation is limited.
- !May 12, 1:30 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY is up ~3% intraday but there are no recent headlines or identifiable catalysts explaining the move, making it difficult to distinguish a sustained trend from a gap or thin-volume spike. The macro context (elevated 5Y inflation expectations) does not directly favor pharmaceutical/biotech names like LLY. With 135 minutes remaining, there is time for continuation, but without a clear news-driven catalyst, mean-reversion risk is meaningful and confidence in directional continuation is limited.
- ?May 12, 1:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY's 2.75% move lacks a clear company-specific catalyst in the available headlines, with the only recent news referencing AMD and growth stocks broadly. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is generally a headwind for high-multiple growth/pharma names like LLY. With 150 minutes remaining there is time for continuation, but without a confirmed fundamental catalyst the move may be mean-reverting or sector-driven noise.
- !May 12, 1:15 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY's 2.75% move lacks a clear company-specific catalyst in the available headlines, with the only recent news referencing AMD and growth stocks broadly. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is generally a headwind for high-multiple growth/pharma names like LLY. With 150 minutes remaining there is time for continuation, but without a confirmed fundamental catalyst the move may be mean-reverting or sector-driven noise.
- ?May 12, 1:01 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY's 2.78% intraday gain lacks a clear stock-specific catalyst in the available headlines, which focus on AMD and unrelated growth stocks. The macro context flags elevated inflation expectations (T5YIE at 1.9σ above trend), which is generally neutral-to-negative for high-multiple pharma names like LLY. With 165 minutes remaining there is time for the move to extend, but without a confirmed fundamental driver the gain could represent profit-taking territory or a broader market lift that may fade into the close.
- !May 12, 1:01 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY's 2.78% intraday gain lacks a clear stock-specific catalyst in the available headlines, which focus on AMD and unrelated growth stocks. The macro context flags elevated inflation expectations (T5YIE at 1.9σ above trend), which is generally neutral-to-negative for high-multiple pharma names like LLY. With 165 minutes remaining there is time for the move to extend, but without a confirmed fundamental driver the gain could represent profit-taking territory or a broader market lift that may fade into the close.
- ?May 12, 12:45 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY has moved up 2.75% today but there is no direct LLY-specific catalyst visible in the provided headlines — the AMD/growth stock headline is not a meaningful driver for a large-cap pharma/biotech name. The macro context shows elevated inflation expectations (T5YIE at 1.9σ above trend), which is generally a headwind for high-multiple growth stocks like LLY rather than a tailwind. With 180 minutes remaining, there is time for movement, but without a clear fundamental catalyst supporting continuation, mean reversion or consolidation is equally plausible.
- !May 12, 12:45 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY has moved up 2.75% today but there is no direct LLY-specific catalyst visible in the provided headlines — the AMD/growth stock headline is not a meaningful driver for a large-cap pharma/biotech name. The macro context shows elevated inflation expectations (T5YIE at 1.9σ above trend), which is generally a headwind for high-multiple growth stocks like LLY rather than a tailwind. With 180 minutes remaining, there is time for movement, but without a clear fundamental catalyst supporting continuation, mean reversion or consolidation is equally plausible.
- ?May 12, 12:30 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up ~2.9% with no direct catalyst visible in the available headlines — the AMD/growth-stock headline is unrelated to LLY's pharma fundamentals, offering no clear sector tailwind. The macro backdrop shows elevated 5-year inflation expectations (2.62, ~1.9σ above trend), which can pressure growth/high-multiple names like LLY near-term rather than support them. With 195 minutes remaining, there is time for the move to extend, but without a confirmed catalyst (earnings beat, clinical data, FDA approval) the gap looks more like a sympathy or broad market lift, suggesting mean-reversion risk is meaningful.
- !May 12, 12:30 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY is up ~2.9% with no direct catalyst visible in the available headlines — the AMD/growth-stock headline is unrelated to LLY's pharma fundamentals, offering no clear sector tailwind. The macro backdrop shows elevated 5-year inflation expectations (2.62, ~1.9σ above trend), which can pressure growth/high-multiple names like LLY near-term rather than support them. With 195 minutes remaining, there is time for the move to extend, but without a confirmed catalyst (earnings beat, clinical data, FDA approval) the gap looks more like a sympathy or broad market lift, suggesting mean-reversion risk is meaningful.
- ?May 12, 12:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up 2.59% today but there is no clear LLY-specific catalyst in the recent headlines — the only headline references AMD and general growth stocks, providing no direct support for continued pharmaceutical sector momentum. The macro backdrop shows elevated 5-year inflation expectations (2.62, ~1.9σ above trend), which is more of a headwind for high-valuation growth/biotech names like LLY than a tailwind. With 210 minutes remaining, there is time for further movement, but without a stock-specific catalyst the move may be consolidation or mean-reversion territory rather than a clean continuation setup.
- !May 12, 12:15 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY is up 2.59% today but there is no clear LLY-specific catalyst in the recent headlines — the only headline references AMD and general growth stocks, providing no direct support for continued pharmaceutical sector momentum. The macro backdrop shows elevated 5-year inflation expectations (2.62, ~1.9σ above trend), which is more of a headwind for high-valuation growth/biotech names like LLY than a tailwind. With 210 minutes remaining, there is time for further movement, but without a stock-specific catalyst the move may be consolidation or mean-reversion territory rather than a clean continuation setup.
- ?May 12, 12:00 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY has moved up 2.72% today but there is no LLY-specific headline or catalyst in the evidence provided to explain or support continuation of this move — the only headline references AMD and growth stocks broadly, which is insufficient to anchor a high-conviction directional call. The macro context (elevated 5-year inflation expectations at 1.9σ above trend) is modestly unfavorable for high-multiple pharmaceutical/biotech names like LLY as it pressures discount rates. With 225 minutes remaining there is time for a move, but without a clear fundamental catalyst the gap-and-hold pattern is uncertain and mean reversion is equally plausible.
- !May 12, 12:00 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY has moved up 2.72% today but there is no LLY-specific headline or catalyst in the evidence provided to explain or support continuation of this move — the only headline references AMD and growth stocks broadly, which is insufficient to anchor a high-conviction directional call. The macro context (elevated 5-year inflation expectations at 1.9σ above trend) is modestly unfavorable for high-multiple pharmaceutical/biotech names like LLY as it pressures discount rates. With 225 minutes remaining there is time for a move, but without a clear fundamental catalyst the gap-and-hold pattern is uncertain and mean reversion is equally plausible.
- ?May 12, 11:45 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY's 2.34% intraday gain lacks a clear LLY-specific catalyst in the provided headlines, which reference AMD and unrelated macro factors — suggesting the move may be sector rotation or broad market lift rather than a fundamental driver. The elevated T5YIE inflation expectation (2.62, nearly 2σ above trend) creates a macro headwind for high-multiple growth/pharma names like LLY, as rate-sensitive valuations face compression pressure. With 240 minutes remaining there is ample time for either direction, but absent a clear LLY-specific catalyst the move is difficult to confidently project as continuing.
- !May 12, 11:45 AMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
LLY's 2.34% intraday gain lacks a clear LLY-specific catalyst in the provided headlines, which reference AMD and unrelated macro factors — suggesting the move may be sector rotation or broad market lift rather than a fundamental driver. The elevated T5YIE inflation expectation (2.62, nearly 2σ above trend) creates a macro headwind for high-multiple growth/pharma names like LLY, as rate-sensitive valuations face compression pressure. With 240 minutes remaining there is ample time for either direction, but absent a clear LLY-specific catalyst the move is difficult to confidently project as continuing.
- ?May 12, 11:30 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
LLY is up ~2.93% today but there is no clear LLY-specific catalyst in the recent headlines — the only headline references AMD and growth stocks broadly, which is tangential at best. The macro context highlights elevated 5-year inflation expectations (2.62, ~1.9σ above trend), which is not a direct tailwind for large-cap pharma/biotech and could weigh on rate-sensitive growth valuations. With ~255 minutes remaining the session is still early, but absent a clear fundamental catalyst the move looks potentially momentum-driven or sector-rotation-based, making continuation uncertain.
- !May 12, 11:30 AMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
LLY is up ~2.93% today but there is no clear LLY-specific catalyst in the recent headlines — the only headline references AMD and growth stocks broadly, which is tangential at best. The macro context highlights elevated 5-year inflation expectations (2.62, ~1.9σ above trend), which is not a direct tailwind for large-cap pharma/biotech and could weigh on rate-sensitive growth valuations. With ~255 minutes remaining the session is still early, but absent a clear fundamental catalyst the move looks potentially momentum-driven or sector-rotation-based, making continuation uncertain.
- ✓May 12, 10:00 AMdecisionacted
Agent VII — Day Trader — decide: buy
LLY reported a 56% year-over-year revenue beat as noted in the CFO commentary headline, providing a strong fundamental catalyst that typically sustains buying momentum throughout the session. With 345 minutes remaining until the forced close cutoff, there is ample time for institutional buyers to add positions following the earnings surprise. The India campaign halt is a minor regulatory headwind but unlikely to overshadow a major revenue beat; sector tailwind from NVO's recent 21% rally in GLP-1/obesity space also supports continued upside for LLY.
- ▢May 11, 8:00 PMjournal
Agent VII — Day Trader opened long 2 @ $986.89
- ▣May 11, 8:00 PMjournalstop
Agent VII — Day Trader closed long 2 @ $967.06 (-$39.65)
Long stop: close $967.06 ≤ stop $972.08
- ❖May 11, 1:20 PMnewsvia finnhub
Advanced Micro Devices and Other Growth Stocks Are Flying High. History Says Hold on to Them.
If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.
- ❖May 11, 11:23 AMnewsvia finnhub
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.
- ❖May 11, 11:18 AMnewsvia finnhub
Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
- ❖May 11, 11:15 AMnewsvia finnhub
Eli Lilly CFO Lucas Montrace Explains What Drove 56% Year-over-Year Revenue Beat
Eli Lilly CFO Lucas Montrace joins Ashley Mastronardi on NYSE Live to discuss his YOY Revenue Beat
- ❖May 11, 11:13 AMnewsvia finnhub
Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity
Eli Lilly pausedits obesity awareness campaign in India after the nation's drugsregulator warned the company it could violate rules againstadvertising prescription medicines to consumers even...
- ❖May 11, 9:50 AMnewsvia finnhub
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- ❖May 11, 9:05 AMnewsvia finnhub
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma MA
- ❖May 11, 8:55 AMnewsvia finnhub
NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
- ❖May 11, 8:55 AMnewsvia finnhub
NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
- ❖May 11, 7:08 AMnewsvia finnhub
Sanofi: Great Yield And Plenty Of Upside Potential
Sanofi (SNY) stock: Strong Buy with 5.5%+ yield, undervalued multiples, and 16â20% projected returns from its robust pipelineâread the thesis here.
- ❖May 11, 6:43 AMnewsvia finnhub
Eli Lilly and Company (NYSE:LLY) Looks Interesting, And It's About To Pay A Dividend
Eli Lilly and Company ( NYSE:LLY ) is about to trade ex-dividend in the next 3 days. The ex-dividend date occurs one...
- ❖May 11, 5:10 AMnewsvia finnhub
Eli Lilly & Co. (NYSE:LLY) Passes the "Little Book That Makes You Rich" Growth Screen
Eli Lilly (LLY) excels in the "Little Book That Makes You Rich" strategy, showing 47% revenue growth, 114% EPS growth, 81% ROE, and consistent earnings surprises, making it a top growth stock candidate.
- ❖May 11, 4:31 AMnewsvia finnhub
Dr. Scott Gottlieb: Could see more hantavirus case, but don't think it will get out of control
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the state of the hantavirus outbreak, risk of a wider outbreak, fate of FDA Commissioner Marty Makary, FDA's new flavored vape policy, and more.
- ❖May 11, 2:35 AMnewsvia finnhub
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.Builds toward the establishment of
- ❖May 11, 12:09 AMnewsvia finnhub
Eli Lilly To Acquire Kelonia Therapeutics
On April 20, 2026, Eli Lilly & Company and Kelonia Therapeutics, Inc. announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expected to close in the second half of 2026....
- ❖May 10, 11:22 PMnewsvia finnhub
Trump Admin Proposes New IVF Benefit To Expand Fertility CoverageThrough Employers
Trump administration proposes new IVF benefits rule aimed at expanding employer fertility coverage and lowering treatment costs.
- ❖May 10, 1:09 PMnewsvia finnhub
Hims Labs AI And GLP 1 Push Test Stock Valuation Story
Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...
- ❖May 10, 3:11 AMnewsvia finnhub
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Eli Lilly is a strong buy as 2026 guidance rose $2B on surging Zepbound sales and deep pipeline momentum. Learn why LLY stock is a strong buy.
- ❖May 9, 6:25 AMnewsvia finnhub
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
The weight loss drug market is on track to reach almost $100 billion.
- ❖May 8, 3:37 PMnewsvia finnhub
Early Eli Lilly stock investors now earn a 9% dividend yield-on-cost
There's a reason the world's most patient investors love dividend stocks. Market movements heavily influence a stock's capital-gains potential in a given year. But dividends are usually paid whether the broader market is up or down, and that dependability is a big reason to factor them in when ...
- ❖May 8, 2:04 PMnewsvia finnhub
Dividend Champion, Contender, And Challenger Highlights: Week Of May 10
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read this week's list here.
- ❖May 8, 12:52 PMnewsvia finnhub
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
- ❖May 8, 11:42 AMnewsvia finnhub
GLP-1 battle heats up between Eli Lilly and Novo Nordisk
BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).
- ❖May 8, 10:30 AMnewsvia finnhub
New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
· Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms. · PatentVest’s report reveals how intellectual property strategy, receptor-ratio engineering, and delivery platforms may determine the next leaders in obesity therapeutics. DALLAS, TX, May 08, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, “The T
- ❖May 8, 9:50 AMnewsvia finnhub
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
The competition is far behind.
- ❖May 8, 9:25 AMnewsvia finnhub
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Tempus AI, Inc. leverages AI precision medicine, genomic diagnostics, & data licensing to scale growth; key metrics & guidance signal upside. Click for more on TEM.
- ❖May 8, 8:07 AMnewsvia finnhub
Omada Health Q1 Earnings Call Highlights
Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D
- ❖May 8, 8:02 AMnewsvia finnhub
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Health officials explored restricting specific antidepressants among SSRI drugs-sources
- ❖May 8, 8:00 AMnewsvia finnhub
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off
Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?
- ❖May 8, 7:33 AMnewsvia finnhub
Lilly to invest extra $4.5B across Indiana manufacturing
The Indianapolis-based company expanded its spend to ensure it can meet growing demand for genetic therapies and weight-loss drugs.
- ❖May 8, 7:16 AMnewsvia finnhub
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following […]
- ❖May 8, 6:29 AMnewsvia finnhub
Acting Labor Secretary Keith Sonderling on jobs data, AI's impact on jobs, interest rates
Acting Labor Secretary Keith Sonderling joins 'Squawk on the Street' to discuss recent jobs data, companies investing in U.S. factories, the federal funds rate, and more.
- ❖May 8, 6:19 AMnewsvia finnhub
Eli Lilly's (NYSE:LLY) Earnings Are Weaker Than They Seem
Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. We did some...
- ❖May 8, 5:01 AMnewsvia finnhub
Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor
The recruitment represents a significant strategic addition to the company as it continues the development of its innovative drug platform within pain and inflammatory diseases. Dr. Lundberg has had a long and highly successful international career spanning both academia and the global pharmaceutical industry. He began his career as a researcher and professor at the Karolinska Institute and established himself at a very early stage as one of the world's 100 most cited scientists.
- ❖May 8, 4:57 AMnewsvia finnhub
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake
Eli Lilly's new oralweight-loss drug, Foundayo, was prescribed 7,335 times in theU.S. in the fourth week, a modest uptake compared to rival NovoNordisk's Wegovy pill, analysts said. ...
- ❖May 7, 7:16 PMnewsvia finnhub
Why AbCellera Biologics (ABCL) Is Up 16.1% After ABCL635 Trial Momentum Builds Ahead Of Data
In recent days, attention has centred on AbCellera Biologics ahead of its upcoming Q1 earnings call and the May 11, 2026 Phase 1 interim data update for ABCL635, a clinical candidate targeting menopause-related vasomotor symptoms. Investor optimism has been reinforced by analyst commentary on the potential competitiveness of ABCL635, growing insider and institutional interest, and AbCellera’s progress in advancing 19 molecules into clinical development across internal and partnered...
- ❖May 7, 6:00 PMnewsvia finnhub
The Agencies Building Pharma's Next Decade Just Picked Their Software: Daily Command Launches With 18 of the Industry's Most Senior Agency Leaders Already Inside It
Doceree, the AI-powered operating system for healthcare marketing, today launched Daily Command — the single product where pharmaceutical brand teams now plan, decide, execute, and measure their day's work — and named the 75 senior industry operators who co-built it.
- ❖May 7, 5:15 PMnewsvia finnhub
75 of Pharma's Most Senior Marketers Just Walked Away From a $12 Billion Tool Stack
75 of the pharmaceutical industry's most senior brand, commercial, and agency leaders today publicly declared the end of the fragmented software stack that has defined pharma marketing for two decades — and put their names on a single new product designed to replace it.
- ❖May 7, 4:20 PMnewsvia finnhub
How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter
IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.
- ❖May 7, 4:10 PMnewsvia finnhub
Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support
Survey of more than 3,000 GLP‑1 patients reveals care gaps and rising out‑of‑pocket costs, underscoring employers’ need to pair flexible GLP‑1 access with ongoing lifestyle supportSAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company’s Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation, prescribing, and ongoing medication management, to employ
- ❖May 7, 3:50 PMnewsvia finnhub
Glucotrack Submits Blood Glucose Monitoring Technology to FDA
By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]
- ❖May 7, 2:39 PMnewsvia finnhub
Novo Nordisk Surges 9.2% As Wegovy Pill Fuels Momentum
Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.
- ❖May 7, 2:35 PMnewsvia finnhub
Forget Eli Lilly: These 2 Stocks Have More Upside
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.
- ❖May 7, 2:33 PMnewsvia finnhub
Lilly Pours $4.5 Billion More Into Indiana
The expansion coincides with an $8 billion bond sale to fund acquisitions
- ❖May 7, 2:05 PMnewsvia finnhub
Amazon Expands GLP 1 Push With Ozempic Pill
Novo partnership deepens Amazon healthcare ambitions
- ❖May 7, 1:30 PMnewsvia finnhub
Is Eli Lilly and Company (LLY) One of the Best Strong Buy Growth Stocks to Buy Right Now?
Eli Lilly and Company (NYSE:LLY) is one of the best strong buy growth stocks to buy right now. Reuters reported on May 1 that Foundayo, which is Eli Lilly and Company’s (NYSE:LLY) newly launched oral weight-loss drug, hit 5,612 prescriptions in the United States in the third week following its launch, as per analysts citing […]
- ❖May 7, 1:26 PMnewsvia finnhub
Cantor Fitzgerald Lifts PT on Eli Lilly and Company (LLY) on Q1 Earnings Call
Eli Lilly and Company (NYSE:LLY) is one of the best strong buy stocks to invest in according to billionaires. Cantor Fitzgerald lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,230 from $1,205 on May 1, reaffirming an Overweight rating on the shares. The firm told investors in a research note that the […]
- ❖May 7, 1:02 PMnewsvia finnhub
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?
Mounjaro generated $8.66 billion in sales in the first quarter.
- ❖May 7, 12:57 PMnewsvia finnhub
Omada Health To Serve As Program Administrator In Eli Lilly's Employer Connect Program
Omada Health (NASDAQ:OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation,
- ❖May 7, 10:33 AMnewsvia finnhub
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.